Molecular structure of Aprepitant, CAS Number: 170729-80-3
Aprepitant (CAS 170729-80-3)
See product citations (4)
Alternate Names:
5-[[(2R,3S)-2-[(1R)-1-[3,5-Bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)-4-morpholinyl]methyl]-1,2-dihydro-3H-1,2,4-triazol-3-one; Emend; MK-0869
Application:
Aprepitant is a selective neurokinin-1 (NK-1) receptor antagonist
CAS Number:
170729-80-3
Purity:
≥99%
Molecular Weight:
534.43
Molecular Formula:
C23H21F7N4O3
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Product Citations
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
A novel selective neurokinin-1 (NK-1) receptor antagonist. In vitro studies using human liver microsomes show that it is metabolized primarily by CYP3A4 with minor metabolism by CYP2C19 and CYP1A2
Aprepitant (CAS 170729-80-3) References
- Prevention of cisplatin-induced emesis by the oral neurokinin-1 antagonist, MK-869, in combination with granisetron and dexamethasone or with dexamethasone alone. | Campos, D., et al. 2001. J Clin Oncol. 19: 1759-67. PMID: 11251007
- Prevention of cisplatin-induced acute and delayed emesis by the selective neurokinin-1 antagonists, L-758,298 and MK-869. | Van Belle, S., et al. 2002. Cancer. 94: 3032-41. PMID: 12115394
- Pharmacokinetics of aprepitant after single and multiple oral doses in healthy volunteers. | Majumdar, AK., et al. 2006. J Clin Pharmacol. 46: 291-300. PMID: 16490805
- Aprepitant boasted a protective effect against olanzapine-induced metabolic syndrome and its subsequent hepatic, renal, and ovarian dysfunction; Role of IGF1/p-AKT/FOXO1 and NFκB/IL-1β/TNF-α signaling pathways in female Wistar albino rats. | Mohyeldin, RH., et al. 2024. Biochem Pharmacol. 221: 116020. PMID: 38237301
- The effect of SP/NK1R on expression and activity of glutaredoxin and thioredoxin proteins in prostate cancer cells. | Zarei Shandiz, S., et al. 2024. Naunyn Schmiedebergs Arch Pharmacol.. PMID: 38334824
- The combined anti-tumor effects of 5-fluorouracil and neurokinin receptor inhibitor, aprepitant, against colorectal cancer: In vitro and in vivo study. | Alalikhan, A., et al. 2024. Med Oncol. 41: 70. PMID: 38340190
- Neurokinin-1 receptor antagonist aprepitant regulates autophagy and apoptosis via ROS/JNK in intrahepatic cholangiocarcinoma. | Yang, Y., et al. 2024. Liver Int. 44: 1651-1667. PMID: 38554043
- Rapid elucidation of agonist-driven regulation of the neurokinin 1 receptor using a GPCR phosphorylation immunoassay. | Blum, NK., et al. 2024. Eur J Pharmacol. 973: 176587. PMID: 38642667
- Aprepitant Alleviates Poststroke Pneumonia in a Mouse Model of Middle Cerebral Artery Occlusion. | Xie, Z., et al. 2024. Rejuvenation Res. 27: 102-109. PMID: 38666697
- Structural optimization affording 2-(R)-(1-(R)-3, 5-bis(trifluoromethyl)phenylethoxy)-3-(S)-(4-fluoro)phenyl-4- (3-oxo-1,2,4-triazol-5-yl)methylmorpholine, a potent, orally active, long-acting morpholine acetal human NK-1 receptor antagonist. | Hale, JJ., et al. 1998. J Med Chem. 41: 4607-14. PMID: 9804700
Inhibitor of:
CCL23, CCL27b, CCRL2, CKR-4, CKR-8, eoxtaxin-3, MrgB2, MRGX2, NK-1R, NK-2R, Olfr380, Preprotachykinin, and PTα.Activator of:
urocortin II.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Aprepitant, 1 mg | sc-207299 | 1 mg | $173.00 |